Inhibrx Biosciences Inc. (INBX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 13 | 7 | 2 | 2 | 0 | 1 | - | - |
| Operating profit | $m | -135 | - | ||||||
| Net profit | $m | -76 | -82 | -145 | -241 | 1,688 | -140 | - | -143 |
| EPS reported | $ | -9.04 | - | ||||||
| Operating cashflow per share | $ | -8.38 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -8.38 | - | ||||||
| Free cash flow | $m | -130 | - | ||||||
| Net debt | $m | -21 | - | ||||||
| Book value equity | $m | 8 | - | ||||||
| Book value per share | $ | 0.52 | - | ||||||
| Number of shares | m | 15.49 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 153.07 | - | ||||||
| P/S LTM | x | 941.13 | - | ||||||
| P/FCF LTM | x | -9.42 | - | ||||||
| EV/EBITDA LTM | x | -9.62 | - | ||||||
| EV/Sales LTM | x | 927.90 | - | ||||||
| Earnings Yield LTM | % | -11.45% | - | ||||||
| FCF Yield | % | -10.61% | - | ||||||
| Quality | |||||||||
| ROE | % | -1752.2% | - | ||||||
| ROIC | % | -1.17% | - | ||||||
| Operating margin | % | -103.87% | - | ||||||
| Gross margin | % | -91.00% | - | ||||||
| FCF/Sales | % | -9986.5% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +550.00% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -1.21 | - | ||||||
| Net Debt/EBITDA | x | 0.14 | - | ||||||
| EBIT/Net interest | x | -11.07 | - | ||||||
| Net debt/market cap | % | +8.41% | - | ||||||
| Net debt/Equity | x | -2.67 | - | ||||||
| Gross debt/equity | x | 13.39 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free